Looking at the stock we see that its previous close was $14.88 and the beta (5Y monthly) reads 0.979 with the day’s price range being $14.43 – $15.09. The company has a trailing 12-month PE ratio of 194.00. In terms of its 52-week price range, SPRY has a high of $18.51 and a low of $7.55. The company’s stock has gained about 27.73% over that past 30 days.
ARS Pharmaceuticals Inc has a market cap of $1.46 billion and is expected to release its quarterly earnings report on 2025-Mar-19.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 7.48M, with a low of 5M and a high of 8.5M. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 83.08M, or -6.80% down from figures reported last year.
On the other hand, looking at the outlook for the SPRY stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 4 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the ARS Pharmaceuticals Inc (SPRY) stock as a Hold, while 4 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the SPRY stock currently stands at 4.41, and the current price level is 12.09% off its SMA20 and 22.21% from its 50-day simple moving average. The RSI (14) is pointing at 66.38 while the volatility over the past week is 5.42% and jumps to 8.73% over the past one month. The beta value is 0.71, while the average true range (ATR) is currently pointing at 0.96. The average price target for the stock over the next 12 months is $22, with the estimates having a low of $18 and a high of $30. These price ends are -20.97% and -101.61% off the current price level respectively, although investors could be excited at the prospect of a -47.85% if the SPRY share price touches on the median price of $22.
Coming back to ARS Pharmaceuticals Inc (NASDAQ:SPRY), we note that the average 3-month trading volume was 1.68 million, while that of the preceding 10-day period stands at 2.02 million. Current shares outstanding are 97.95 million.
The insiders hold 42.88% of the company’s shares while institutions hold 50.48%. The data shows that short shares as of 2025-03-31, stood at 17.15 million at a short ratio of 8.66. This represents a 3259.00 short interest in shares outstanding on 2025-03-31. Shares short fall in March from the previous month at 19.0 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 41.04% up in year-to-date price movement.
